Aytu BioPharma 관리

관리 기준 확인 2/4

Aytu BioPharma CEO는 Josh Disbrow, Apr2015 에 임명되었습니다 의 임기는 9.58 년입니다. 총 연간 보상은 $ 928.22K, 63.6% 로 구성됩니다. 63.6% 급여 및 36.4% 보너스(회사 주식 및 옵션 포함). 는 $ 114.73K 가치에 해당하는 회사 주식의 1.17% 직접 소유합니다. 114.73K. 경영진과 이사회의 평균 재임 기간은 각각 2.4 년과 8.3 년입니다.

주요 정보

Josh Disbrow

최고 경영자

US$928.2k

총 보상

CEO 급여 비율	63.6%
CEO 임기	9.6yrs
CEO 소유권	1.2%
경영진 평균 재임 기간	2.4yrs
이사회 평균 재임 기간	8.3yrs

최근 관리 업데이트

Recent updates

CEO 보상 분석

Josh Disbrow 의 보수는 Aytu BioPharma 의 수익과 비교하여 어떻게 변경되었나요?
날짜	총 보상	급여	회사 수익
Sep 30 2024	n/a	n/a	-US$7m
Jun 30 2024	US$928k	US$590k	-US$16m
Mar 31 2024	n/a	n/a	-US$13m
Dec 31 2023	n/a	n/a	-US$17m
Sep 30 2023	n/a	n/a	-US$24m
Jun 30 2023	US$708k	US$590k	-US$17m
Mar 31 2023	n/a	n/a	-US$31m
Dec 31 2022	n/a	n/a	-US$77m
Sep 30 2022	n/a	n/a	-US$82m
Jun 30 2022	US$590k	US$590k	-US$109m
Mar 31 2022	n/a	n/a	-US$112m
Dec 31 2021	n/a	n/a	-US$84m
Sep 30 2021	n/a	n/a	-US$82m
Jun 30 2021	US$6m	US$545k	-US$58m
Mar 31 2021	n/a	n/a	-US$42m
Dec 31 2020	n/a	n/a	-US$22m
Sep 30 2020	n/a	n/a	-US$13m
Jun 30 2020	US$2m	US$608k	-US$14m
Mar 31 2020	n/a	n/a	-US$25m
Dec 31 2019	n/a	n/a	-US$24m
Sep 30 2019	n/a	n/a	-US$29m
Jun 30 2019	US$1m	US$330k	-US$27m
Mar 31 2019	n/a	n/a	-US$12m
Dec 31 2018	n/a	n/a	-US$10m
Sep 30 2018	n/a	n/a	-US$9m
Jun 30 2018	US$606k	US$303k	-US$10m

보상 대 시장: Josh 의 총 보상 ($USD 928.22K )은 UK 시장( $USD 353.74K ).

보상과 수익: 회사가 수익성이 없는 동안 Josh 의 보상이 증가했습니다.

CEO

Josh Disbrow (49 yo)

9.6yrs

테뉴어

US$928,217

보상

Mr. Joshua R. Disbrow, also known as Josh, serves as Chief Executive Officer at Aytu Biopharma, Inc. since April 16, 2015 and served as its Chairman until 2024. He served as President at Aytu Biopharma, In...

리더십 팀

이름	위치	테뉴어	보상	소유권
Joshua Disbrow	CEO & Director	9.6yrs	US$928.22k	1.17% $ 114.7k
Jarrett Disbrow	Chief Business Officer	2yrs	US$542.10k	0.21% $ 20.5k
Greg Pyszczymuka	Chief Commercial Officer	2.8yrs	US$516.30k	0.38% $ 37.1k
Ryan Selhorn	CFO, Corporate Secretary & Treasurer	no data	데이터 없음	0.26% $ 25.4k
Margaret Cabano	Vice President of Operations	no data	데이터 없음	데이터 없음

2.4yrs

평균 재임 기간

46.5yo

평균 연령

경험이 풍부한 관리: 0A8M 의 관리팀은 경험 ( 2.4 년 평균 재직 기간)으로 간주됩니다.

이사회 구성원

이름	위치	테뉴어	보상	소유권
Joshua Disbrow	CEO & Director	8.8yrs	US$928.22k	1.17% $ 114.7k
Vivian Liu	Independent Director	2.3yrs	US$77.60k	0.16% $ 15.7k
John Donofrio	Independent Chairman	8.3yrs	US$107.60k	0.061% $ 6.0k
Carl Dockery	Independent Director	8.6yrs	US$72.60k	0.17% $ 16.7k
Abhinav Jain	Independent Director	1.4yrs	US$79.30k	0.15% $ 15.2k

8.3yrs

평균 재임 기간

57yo

평균 연령

경험이 풍부한 이사회: 0A8M 의 이사회는 경험(평균 재직 기간 8.3 년)으로 간주됩니다.

Aytu BioPharma 관리

관리 기준 확인 2/4

주요 정보

최근 관리 업데이트

Russ McMahen to Leave as Senior Vice President of Research and Development of Aytu BioPharma, Inc

Aytu BioPharma, Inc., Annual General Meeting, Jun 26, 2024

Aytu BioPharma, Inc. Appoints Abhinav "Abi" Jain as Board of Directors

Gary Cantrell to Retire from the Aytu BioPharma, Inc.'s Board of Directors, Effective December 31, 2022

Aytu BioPharma, Inc. Announces the Passing of Michael Macaluso, Board Member

Aytu BioPharma, Inc. Announces Management Changes

Recent updates

First quarter 2025 earnings released: EPS: US$0.18 (vs US$1.48 loss in 1Q 2024)

Russ McMahen to Leave as Senior Vice President of Research and Development of Aytu BioPharma, Inc

Aytu BioPharma, Inc. to Report Q1, 2025 Results on Nov 13, 2024

Full year 2024 earnings released: US$2.86 loss per share (vs US$5.11 loss in FY 2023)

Aytu BioPharma, Inc. to Report Q4, 2024 Results on Sep 26, 2024

An unknown buyer acquired Innovus Pharmaceuticals, Inc. from Aytu BioPharma, Inc. (NasdaqCM:AYTU).

New minor risk - Shareholder dilution

Third quarter 2024 earnings released: US$0.52 loss per share (vs US$1.93 loss in 3Q 2023)

Aytu BioPharma, Inc., Annual General Meeting, Jun 26, 2024

Aytu BioPharma, Inc. to Report Q3, 2024 Results on May 15, 2024

Second quarter 2024 earnings released: US$0.04 loss per share (vs US$2.15 loss in 2Q 2023)

Aytu BioPharma, Inc. to Report Q2, 2024 Results on Feb 14, 2024

Aytu BioPharma, Inc. to Report Q1, 2024 Results on Nov 14, 2023

Aytu BioPharma, Inc. Announces Approval of the Cotempla XR-ODT Manufacturing Site Transfer Prior Approval Supplement

Aytu BioPharma, Inc. announced delayed annual 10-K filing

Full year 2023 earnings released: US$5.11 loss per share (vs US$74.95 loss in FY 2022)

Aytu BioPharma, Inc. to Report Q4, 2023 Results on Sep 27, 2023

No longer forecast to breakeven

Aytu BioPharma, Inc. Announces Submission of Cotempla XR-ODT(R) Manufacturing Site Transfer Prior Approval Supplement

Aytu BioPharma, Inc. has completed a Follow-on Equity Offering in the amount of $3.999955 million.

Aytu BioPharma, Inc. Appoints Abhinav "Abi" Jain as Board of Directors

Third quarter 2023 earnings released: US$1.93 loss per share (vs US$35.75 loss in 3Q 2022)

Forecast to breakeven in 2024

Aytu BioPharma, Inc. announced delayed 10-Q filing

Aytu BioPharma, Inc. to Report Q2, 2023 Results on Feb 14, 2023

Aytu Biopharma Regains Nasdaq Minimum Bid Price Compliance

Aytu Biopharma, Inc. Continues Availability of Adzenys XR-ODT(R) as the Only FDA-Approved Orally Disintegrating Tablet (ODT) Medication That Is Bioequivalent to Adderall XR(R) for Adhd Patients

Forecast to breakeven in 2025

Gary Cantrell to Retire from the Aytu BioPharma, Inc.'s Board of Directors, Effective December 31, 2022

Aytu BioPharma Receives A 180-Day Extension by Nasdaq to Regain Compliance with Bid Price Rule

Forecast to breakeven in 2025

Aytu BioPharma, Inc. Announces the Passing of Michael Macaluso, Board Member

Aytu BioPharma, Inc. Announces Management Changes

Aytu BioPharma, Inc. to Report Q1, 2023 Results on Nov 14, 2022

Aytu Biopharma Announces Continuing Availability of Adhd Medication Adzenys Xr-Odt(R) in Response to Reported Generic Adderall(R) Xr Supply Disruptions

Full year 2022 earnings released: US$3.75 loss per share (vs US$3.48 loss in FY 2021)

Aytu BioPharma, Inc. to Report Q4, 2022 Results on Sep 27, 2022

Aytu BioPharma, Inc. Announces Addition of Fourth Patent License for Ar101/Enzastaurin

Aytu BioPharma, Inc. has completed a Follow-on Equity Offering in the amount of $9.99825 million.

Aytu BioPharma, Inc. has completed a Follow-on Equity Offering in the amount of $9.99825 million.

High number of new directors

Aytu Biopharma, Inc. Appoints Vivian Liu to Its Board of Directors and as Member of the Nominating & Corporate Governance Committee, Effective July 1, 2022

Aytu BioPharma Receives Letter from the Nasdaq

Insufficient new directors

Third quarter 2022 earnings released: US$1.79 loss per share (vs US$1.41 loss in 3Q 2021)

Insufficient new directors

Aytu BioPharma, Inc., Annual General Meeting, May 18, 2022

Insufficient new directors

Denovo Biopharma LLC Announces Partner Aytu BioPharma Receives FDA Clearance and Orphan Drug Designation for Enzastaurin in Vascular Ehlers-Danlos Syndrome

First quarter 2022 earnings released: US$1.09 loss per share (vs US$0.35 loss in 1Q 2021)

Forecast to breakeven in 2023

Full year 2021 earnings released: US$3.48 loss per share (vs US$3.01 loss in FY 2020)

Forecast to breakeven in 2023

Insufficient new directors

Insufficient new directors

Insufficient new directors

Insufficient new directors

Insufficient new directors

Independent Director Steven Boyd has left the company

Aytu Biopharma, Inc.(NasdaqCM:AYTU) dropped from Russell 3000E Value Index

Aytu Biopharma, Inc. Plans to Close Grand Prairie, Texas Manufacturing Operations over the Next Eighteen Months

CEO 보상 분석

CEO

테뉴어

보상

리더십 팀

평균 재임 기간

평균 연령

이사회 구성원